Billionaire hedge fund managers Ray Dalio and Cathie Wood, known for sharply contrasting investment philosophies, have found common ground in two major equities: Eli Lilly (LLY) and Nvidia (NVDA). Analysis of second-quarter 13F filings by Insider Monkey shows that Bridgewater Associates and ARK Invest maintained significant overlapping positions in both stocks, signaling a rare convergence between Bridgewater’s diversified, macro-driven approach and ARK’s concentrated focus on disruptive innovation.

Market Context

The shared holdings highlight a divergence in positioning strategies for the quarter. While both firms increased their exposure to Eli Lilly, their actions on Nvidia were diametrically opposed. Bridgewater reduced its Nvidia stake by 826,808 shares, bringing its total holding to 3.87 million shares valued at approximately $773.6 million at the end of the second quarter. In contrast, ARK Invest added 345,821 Nvidia shares, ending the quarter with 1.38 million shares valued at roughly $276.4 million.

Analysis

The data suggests that while both firms see long-term value in these assets, their risk management frameworks are driving different tactical moves. Bridgewater, which balances exposure across assets and economic environments, appears to be taking profits or rebalancing its large Nvidia position. Conversely, ARK’s aggressive accumulation of Nvidia and Eli Lilly aligns with its thesis of doubling down on companies it believes will benefit from structural growth trends.

Regarding Eli Lilly, both firms increased their positions, albeit with different magnitudes. Bridgewater added 16,211 shares, resulting in a holding of 87,023 shares worth about $104.4 million. ARK made a more substantial addition, buying 64,578 shares to reach a total of 77,254 shares valued at approximately $92.7 million.

The bullish case for Eli Lilly centers on the expansion of its obesity and diabetes franchise, led by Mounjaro and Zepbound. Company revenue climbed 48% year over year in the second quarter, driven by strong demand for these medicines. Bulls argue this growth trajectory supports earnings expansion for years, capitalizing on the large and growing market for weight-loss treatments.

However, bears caution that much of this opportunity is already priced in. Eli Lilly trades at a forward non-GAAP P/E of 30.39, representing a 61.25% premium to the healthcare sector median of 18.85. Its trailing non-GAAP P/E of 35.43 is approximately 94% above the sector median. While the forward non-GAAP PEG ratio of 1.44 is below the sector median of 1.79, suggesting the valuation is less demanding on a growth-adjusted basis, bears argue the premium leaves the stock vulnerable if GLP-1 sales growth begins to normalize.

Key Numbers

- Bridgewater Nvidia position: 3.87 million shares worth ~$773.6 million (reduced by 826,808 shares in Q2).

- ARK Nvidia position: 1.38 million shares worth ~$276.4 million (added 345,821 shares in Q2).

- Bridgewater Eli Lilly position: 87,023 shares worth ~$104.4 million (added 16,211 shares in Q2).

- ARK Eli Lilly position: 77,254 shares worth ~$92.7 million (added 64,578 shares in Q2).

- Eli Lilly Q2 Revenue Growth: 48% year over year.

- Eli Lilly Forward Non-GAAP P/E: 30.39 (61.25% premium to healthcare sector median of 18.85).

- Eli Lilly Forward Non-GAAP PEG: 1.44 (below sector median of 1.79).

What to Watch

Traders should monitor upcoming quarterly earnings from Eli Lilly and Nvidia for signs of demand normalization in the GLP-1 and AI hardware sectors, respectively. The divergence in positioning between Bridgewater and ARK on Nvidia may indicate differing views on the sustainability of the AI-driven rally versus broader macroeconomic headwinds. Additionally, watch for further 13F filings to see if Bridgewater continues to trim its tech exposure while ARK maintains its aggressive accumulation strategy.